Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Nerve-Blocking drug stop the worst headaches after a brain bleed?

NCT ID NCT07816159

Symptom relief Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers test whether infusing lidocaine into the middle meningeal artery reduces headache severity in adults who have had a bleeding brain aneurysm. Participants receive either lidocaine or a saline placebo during their endovascular aneurysm repair. The trial measures headache intensity over the first 72 hours and tracks opioid use and overall relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lidocaine hydrochloride, a local anesthetic, infused into the middle meningeal artery
What this could lead to
If it works, this could give doctors a targeted way to relieve severe headaches after a bleeding brain aneurysm, possibly reducing the need for opioid painkillers.
What could go wrong
This is a Phase 2 trial with 90 participants, so results may not hold in larger groups. The infusion carries risks such as allergic reactions or unintended effects of lidocaine reaching the brain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. Age ≥ 18 years 2. Imaging showing a SAH and intracranial aneurysm 3. Undergo endovascular therapy within 72 hours\* 4. Glasgow coma scale (GCS) score of 14-15 5. Maximum headache severity of NRS score ≥ 4 at a time \> 1 hour after ictus or the ad-ministration of opioids due to headache Exclusion criteria 6. The patient is unable to understand information provided in the national language or English 7. Known allergies to amide-type local anesthetics or iodinated contrast media 8. Pregnancy or lactation 9. Severe hepatic impairment 10. History of epilepsy 11. History of chronic opioid use 12. Renal impairment with eGFR \< 30 mL/min/1.73m2 13. Current treatment with class III antiarrhythmics (e.g. amiodarone) 14. Atrioventricular block of II and III degree 15. Unsuccessful endovascular aneurysm securement or procedural complications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysmal subarachnoid hemorrhage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage Headache subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Headaches associated with subarachnoid hemorrhage (SAH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.